Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a)

被引:3
|
作者
Schwarz, Andrea [1 ,2 ,3 ,4 ,5 ]
Demuth, Ilja [1 ,2 ,3 ,4 ,6 ]
Landmesser, Ulf [7 ,8 ,9 ]
Haghikia, Arash [7 ,8 ,9 ]
Konig, Maximilian [1 ,2 ,3 ,4 ]
Steinhagen-Thiessen, Elisabeth [1 ,2 ,3 ,4 ,10 ]
机构
[1] Charite Univ Med Berlin, Dept Endocrinol & Metab Dis, Including Div Lipid Metab, Augustenburger Pl 1, D-13353 Berlin, Germany
[2] Charite Univ Med Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[3] Free Univ Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[4] Humboldt Univ, Biol Aging Working Grp, Augustenburger Pl 1, D-13353 Berlin, Germany
[5] Charite Univ Med Berlin, Div Cardiol, Dept Pediat, Berlin, Germany
[6] BCRT Berlin Inst Hlth Ctr Regenerat Therapies, Berlin, Germany
[7] Charith Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany
[8] Charite Univ Med Berlin, Dept Cardiol, Campus Benjamin Franklin, Berlin, Germany
[9] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany
[10] Univ Rostock, Inst Clin Chem & Lab Med, Rostock, Germany
关键词
LDL-cholesterol; Treatment goal achievement; Familial hypercholesterolemia; Lipoprotein (a); Coronary artery disease; Lipid-lowering treatment; Family history; LIPID-MODIFYING THERAPY; CARDIOVASCULAR RISK; HEART-DISEASE; ASSOCIATION; EZETIMIBE; HISTORY; ATORVASTATIN; SIMVASTATIN; GUIDELINE; DIAGNOSIS;
D O I
10.1186/s12944-022-01708-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background Although potent lipid-lowering therapies are available, patients commonly fall short of recommended low-density lipoprotein cholesterol (LDL-C) levels. The aim of this study was to examine the relationship between familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] and LDL-C goal attainment, as well as the prevalence and severity of coronary artery disease (CAD). Moreover, we characterized patients failing to meet recommended LDL-C goals. Methods We performed a cross-sectional analysis in a cohort of patients undergoing cardiac catheterization. Clinical FH was determined by the Dutch Clinical Lipid Network Score, and Lp(a) >= 50 mg/dL (approximate to 107 nmol/L) was considered elevated. Results A total of 838 participants were included. Overall, the prevalence of CAD was 72%, and 62% received lipid-lowering treatment. The prevalence of clinical FH (probable and definite FH) was 4%, and 19% had elevated Lp(a) levels. With 35%, LDL-C goal attainment was generally poor. Among the participants with clinical FH, none reached their LDL-C target. Among patients with elevated Lp(a), LDL-C target achievement was only 28%. The prevalence and severity of CAD were higher in participants with clinical FH (86% prevalence) and elevated Lp(a) (80% prevalence). Conclusion Most participants failed to meet their individual LDL-C goals according to the ESC 2016 and 2019 guidelines. In particular, high-risk patients with clinical FH or elevated Lp(a) rarely met their target for LDL-C. The identification of these patients and more intense treatment approaches are crucial for the improvement of CAD primary and secondary prevention.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Influence of the IDOL Gene Variants on Low-Density Lipoprotein Cholesterol Levels in Turkish Patients with Familial Hypercholesterolemia
    Duymus, Fahrettin
    Kocak, Nadir
    Ozdemir, Ebru Marzioglu
    Esin, Deniz
    Korez, Muslu Kazim
    Cora, Tulun
    MOLECULAR SYNDROMOLOGY, 2024,
  • [32] Effect of Cumulative Exposure to Low-Density Lipoprotein-Cholesterol on Cardiovascular Events in Patients With Familial Hypercholesterolemia
    Tada, Hayato
    Okada, Hirofumi
    Nohara, Atsushi
    Yamagishi, Masakazu
    Takamura, Masayuki
    Kawashiri, Masa-aki
    CIRCULATION JOURNAL, 2021, 85 (11) : 2073 - +
  • [33] Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
    Akdim, Fatima
    Visser, Maartje E.
    Tribble, Diane L.
    Baker, Brenda F.
    Stroes, Erik S. G.
    Yu, Rosie
    Flaim, Joann D.
    Su, John
    Stein, Evan A.
    Kastelein, John J. P.
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (10): : 1413 - 1419
  • [34] Low-density lipoprotein apheresis in homozygous familial hypercholesterolemia
    Mora, C
    Teruel, JL
    Navarro, JF
    AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (02): : 202 - 203
  • [35] ABNORMAL LOW-DENSITY LIPOPROTEIN COMPOSITION IN FAMILIAL HYPERCHOLESTEROLEMIA
    JADHAV, AV
    THOMPSON, GR
    CLINICAL SCIENCE AND MOLECULAR MEDICINE, 1977, 52 (02): : P18 - P19
  • [36] Approach to patients with elevated low-density lipoprotein cholesterol levels
    Feingold, Kenneth R.
    Chait, Alan
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 37 (03)
  • [37] Association of Low-Density Lipoprotein Cholesterol With Risk of Aortic Valve Stenosis in Familial Hypercholesterolemia
    Mundal, Liv J.
    Hovland, Anders
    Igland, Jannicke
    Veierod, Marit B.
    Holven, Kirsten B.
    Bogsrud, Martin Proven
    Tell, Grethe S.
    Leren, Trond P.
    Retterstol, Kjetil
    JAMA CARDIOLOGY, 2019, 4 (11) : 1156 - 1159
  • [38] Low-density lipoprotein apheresis for the treatment of familial hypercholesterolemia
    Khan, T.
    Chandra, K. M.
    Pham, B.
    VALUE IN HEALTH, 2008, 11 (03) : A208 - A209
  • [39] Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events
    Foley, KA
    Simpson, RJ
    Crouse, JR
    Weiss, TW
    Markson, LE
    Alexander, CM
    AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (01): : 79 - 81
  • [40] Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients
    Foody, JoAnne M.
    Sajjan, Shiva G.
    Hu, X. Henry
    Ramey, Dena R.
    Neff, David R.
    Tershakovec, Andrew M.
    Tomassini, Joanne E.
    Wentworth, Chuck
    Tunceli, Kaan
    JOURNAL OF CLINICAL LIPIDOLOGY, 2010, 4 (02) : 126 - 132